tetano
Editor, Senior Moderator
PLoS One
. 2022 Aug 15;17(8):e0273097.
doi: 10.1371/journal.pone.0273097. eCollection 2022.
Clinical features and severe acute respiratory syndrome-coronavirus-2 structural protein-based serology of Mexican children and adolescents with coronavirus disease 2019
Karen Cortés-Sarabia[SUP] 1 [/SUP], Armando Cruz-Rangel[SUP] 2 [/SUP], Alejandro Flores-Alanis[SUP] 3 [/SUP], Marcela Salazar-García[SUP] 4 5 [/SUP], Samuel Jiménez-García[SUP] 6 [/SUP], Griselda Rodríguez-Martínez[SUP] 5 [/SUP], Juan Pablo Reyes-Grajeda[SUP] 2 [/SUP], Rosa Isela Rodríguez-Téllez[SUP] 7 [/SUP], Genaro Patiño-López[SUP] 7 [/SUP], Israel Parra-Ortega[SUP] 8 [/SUP], Oscar Del Moral-Hernández[SUP] 9 [/SUP], Berenice Illades-Aguiar[SUP] 6 [/SUP], Miguel Klünder-Klünder[SUP] 10 [/SUP], Horacio Márquez-González[SUP] 11 [/SUP], Adrián Chávez-López[SUP] 12 [/SUP], Victor M Luna-Pineda[SUP] 5 7 [/SUP]
Affiliations
Abstract
Severe acute respiratory syndrome (SARS)-coronavirus (CoV)-2 infection in children and adolescents primarily causes mild or asymptomatic coronavirus disease 2019 (COVID-19), and severe illness is mainly associated with comorbidities. However, the worldwide prevalence of COVID-19 in this population is only 1%-2%. In Mexico, the prevalence of COVID-19 in children has increased to 10%. As serology-based studies are scarce, we analyzed the clinical features and serological response (SARS-CoV-2 structural proteins) of children and adolescents who visited the Hospital Infantil de México Federico Gómez (October 2020-March 2021). The majority were 9-year-old children without comorbidities who were treated as outpatients and had mild-to-moderate illness. Children aged 6-10 years and adolescents aged 11-15 years had the maximum number of symptoms, including those with obesity. Nevertheless, children with comorbidities such as immunosuppression, leukemia, and obesity exhibited the lowest antibody response, whereas those aged 1-5 years with heart disease had the highest levels of antibodies. The SARS-CoV-2 spike receptor-binding domain-localized peptides and M and E proteins had the best antibody response. In conclusion, Mexican children and adolescents with COVID-19 represent a heterogeneous population, and comorbidities play an important role in the antibody response against SARS-CoV-2 infection.
. 2022 Aug 15;17(8):e0273097.
doi: 10.1371/journal.pone.0273097. eCollection 2022.
Clinical features and severe acute respiratory syndrome-coronavirus-2 structural protein-based serology of Mexican children and adolescents with coronavirus disease 2019
Karen Cortés-Sarabia[SUP] 1 [/SUP], Armando Cruz-Rangel[SUP] 2 [/SUP], Alejandro Flores-Alanis[SUP] 3 [/SUP], Marcela Salazar-García[SUP] 4 5 [/SUP], Samuel Jiménez-García[SUP] 6 [/SUP], Griselda Rodríguez-Martínez[SUP] 5 [/SUP], Juan Pablo Reyes-Grajeda[SUP] 2 [/SUP], Rosa Isela Rodríguez-Téllez[SUP] 7 [/SUP], Genaro Patiño-López[SUP] 7 [/SUP], Israel Parra-Ortega[SUP] 8 [/SUP], Oscar Del Moral-Hernández[SUP] 9 [/SUP], Berenice Illades-Aguiar[SUP] 6 [/SUP], Miguel Klünder-Klünder[SUP] 10 [/SUP], Horacio Márquez-González[SUP] 11 [/SUP], Adrián Chávez-López[SUP] 12 [/SUP], Victor M Luna-Pineda[SUP] 5 7 [/SUP]
Affiliations
- PMID: 35969583
- DOI: 10.1371/journal.pone.0273097
Abstract
Severe acute respiratory syndrome (SARS)-coronavirus (CoV)-2 infection in children and adolescents primarily causes mild or asymptomatic coronavirus disease 2019 (COVID-19), and severe illness is mainly associated with comorbidities. However, the worldwide prevalence of COVID-19 in this population is only 1%-2%. In Mexico, the prevalence of COVID-19 in children has increased to 10%. As serology-based studies are scarce, we analyzed the clinical features and serological response (SARS-CoV-2 structural proteins) of children and adolescents who visited the Hospital Infantil de México Federico Gómez (October 2020-March 2021). The majority were 9-year-old children without comorbidities who were treated as outpatients and had mild-to-moderate illness. Children aged 6-10 years and adolescents aged 11-15 years had the maximum number of symptoms, including those with obesity. Nevertheless, children with comorbidities such as immunosuppression, leukemia, and obesity exhibited the lowest antibody response, whereas those aged 1-5 years with heart disease had the highest levels of antibodies. The SARS-CoV-2 spike receptor-binding domain-localized peptides and M and E proteins had the best antibody response. In conclusion, Mexican children and adolescents with COVID-19 represent a heterogeneous population, and comorbidities play an important role in the antibody response against SARS-CoV-2 infection.